VivoSeq
Other

Rivaroxaban

0

Pipeline Programs↗

10

Active Trials↗

3

Companies Involved↗

Rivaroxaban is an early-stage landscape with 0 programs across 3 companies. The most active players are Bayer, Johnson & Johnson, AMAG Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalA

AMAG Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

70

clinical trials

Completed50 · 71%
Unknown status7 · 10%
Recruiting7 · 10%
Not yet recruiting2 · 3%
Withdrawn1 · 1%
No longer available1 · 1%
Other2 · 3%

Clinical Trials

Trial Activity

70 trials

Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization
Recruiting·—·Phase 4·NCT06812455·80 enrolled
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Recruiting·SScience Valley Research Institute·Phase 4·NCT06873321·100 enrolled
Excretion of Rivaroxaban in Human Breast Milk
Recruiting·TThomas Jefferson University·Phase 1·NCT06831474·10 enrolled
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
Recruiting·—·N/A·NCT06371170·20 enrolled
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
Recruiting·OOttawa Hospital Research Institute·Phase 2/3·NCT06965998·50 enrolled
Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
Recruiting·—·Phase 4·NCT07243080·212 enrolled
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT03630055·1,800 enrolled
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07195812·60 enrolled
Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT05487950·550 enrolled
Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves
Enrolling by invitation·—·Phase 3·NCT07456085·60 enrolled
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Completed·Bayer logoBayer·N/A·NCT05112666·2,601 enrolled
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02846532·112 enrolled
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
Completed·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT04424381·72 enrolled
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Completed·IInstituto Mexicano del Seguro Social·Phase 2/3·NCT05515120·58 enrolled
Rivaroxaban for Antiphospholipid Antibody Syndrome
Completed·SSt. Joseph's Healthcare Hamilton·Phase 4·NCT02116036·81 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)